Curis | search
Click here to view Curis news from 60+ newspapers.
Bookmark or Share- CA-170 - Curis, IncAs part of the collaboration with Aurigene, in October 2015, Curis licensed a first-in-class oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA, both of which function as negative checkpoint regulators of immune activation.
- Curis Provides Third Quarter 2024 Business UpdateLEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended
- Home - Curis, IncCuris is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.
- Company Overview - Curis, IncAt Curis, we apply this meaning to cancer, by developing novel therapies for slowing or preventing the progression of cancer and prolonging life – or closing and curi͒ng cancer.
- Emavusertib (CA-4948) - Curis, IncAs part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally-available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948). For more information on current trials click here .
More
